Kimberly-Clark Readies to Monetize 62 Million Cases of the Common Cold

Kimberly-Clark (NYSE:KMB) has introduced Kleenex Cool Touch tissue, the first-of-its-kind tissue that provides a cooling sensation to soothe a sore nose, and announced that it would be available in retail market in September, just in time for cold and flu season. As per the National Institute of Allergy and Infectious Diseases, more than 62 million cases of the common cold are reported in the United States, with the majority occurring in the fall and winter season.

Kimberly-Clark intends to position Kleenex Cool Touch tissues as a high-value product and thus priced it at a 65% premium to regular Kleenex. Shares of Kimberly-Clark (NYSE:KMB) closed the day up 0.37%. Other competitive consumer staples (NYSE:XLP) up on the day include Procter & Gamble (NYSE:PG) and Johnson & Johnson (NYSE:JNJ).

Don’t Miss: Your Cheat Sheet to the Money Gushing Tobacco Industry.